预约演示
更新于：2025-05-15
Loratadine
氯雷他定
更新于：2025-05-15
概要
基本信息
简介Claritin（氯雷他定）是一种常用于治疗花粉热和荨麻疹等过敏症的药物。 它属于第二代抗组胺药家族，口服。 虽然常见的副作用包括口干、嗜睡和头痛，但过敏反应、癫痫发作和肝脏问题等严重副作用很少见。 氯雷他定在怀孕期间通常被认为是安全的，但其在这一人群中的作用尚未得到很好的研究。 两岁以下的儿童不应服用这种药物。 氯雷他定于 1980 年获得专利，并于 1988 年首次上市。它被世界卫生组织列为基本药物，可作为仿制药使用。 在美国，它可以在柜台购买，是 2020 年最常用的处方药之一，有超过 900 万张处方。 |
药物类型 小分子化药 |
别名 Loratadine (JAN/USP/INN)、Loratadine Effervescent、Loratadine Hydrochloride + [56] |
作用方式 拮抗剂 |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-04-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H23ClN2O2 |
InChIKeyJCCNYMKQOSZNPW-UHFFFAOYSA-N |
CAS号79794-75-5 |
关联
80
项与 氯雷他定 相关的临床试验NCT06955741
A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants
ACTRN12624000019505
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Two-Way Crossover, Bioequivalence Study of Loratadine 5mg Chewable Tablets of AFT Pharmaceuticals, Australia Compared with Children's Claratyne® Grape 5 mg Chewable Tablets in Healthy Human Adult Subjects Under Fasting Conditions.
CTRI/2024/12/077559
An Open Label Balanced Randomized Single Dose Two Treatment Three Sequence Three Period Partial Replicate Reference Scaled Average Oral Bioequivalence Study Comparing Loratadine 1 mg/mL Oral Liquid Solution 10 X 1 mg/mL Manufactured at S Kant Healthcare Ltd for Neo Health OTC Pty Ltd with Childrens Claratyne Loratadine 1 mg/mL Peach Flavour Oral Liquid Solution Bottle 10 X 1 mg/mL Aust R 44453) distributed by Bayer Australia Ltd in Healthy Adult Human Subjects Under Fasting Conditions - NIL
100 项与 氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 氯雷他定 相关的专利（医药）
登录后查看更多信息
3,223
项与 氯雷他定 相关的文献（医药）2025-06-01MARINE POLLUTION BULLETIN
A robust method to quantify pharmaceuticals for the United Nations endorsed Global Estuaries Monitoring (GEM) Programme
Article
作者: Xu, Shaopeng ; Zhou, Guang-Jie ; Lai, Racliffe Weng Seng ; Chen, Chong ; Adedipe, Demilade T ; Luo, Qiong ; Brooks, Bryan W ; Leung, Kenneth Mei Yee ; Boxall, Alistair B A
Following human and animal consumption, pharmaceuticals often remain incompletely metabolized, entering aquatic ecosystems via sources like wastewater discharges, landfill leachates, and aquaculture farms, thereby eventually reaching the ocean through estuaries. This influx poses a significant threat to marine ecosystems. The Global Estuaries Monitoring (GEM) Programme, endorsed by the United Nations Decade of Ocean Science for Sustainable Development (2021-2030), aims to establish a standardized method for monitoring pharmaceuticals in the world's estuaries. This study was performed for simultaneously quantifying 65 pharmaceuticals in small-volume of water samples. The findings revealed that using 20 mL water yielded optimal recoveries between 60 % and 130 %. The influence of pH, salinity and sample matrix on the performance of the method was minimal. 45-50 pharmaceuticals remained stable over a seven-day storage period at both 4 °C and 25 °C. This cost-effective and user-friendly method paves the way for the GEM Programme to monitor pharmaceuticals in over 100 estuaries worldwide.
2025-06-01MARINE POLLUTION BULLETIN
Nontargeted screening of contaminants of emerging concern in the Nandu River Estuary
Article
作者: Cao, Qingyang ; Liu, He ; Yang, Jingjing ; Li, Yihao ; Shi, Liangliang ; Deng, Yu ; Ma, Yini ; Jia, Wenhao ; Huang, Kaibo
Contaminants of emerging concern (CECs) in estuaries have received increasing attention due to their potential environmental impacts. However, detailed analyses of the sources, transport mechanisms, and environmental consequences of these contaminants remain limited. This study applied non-target screening technology to comprehensively assess CECs in the Nandu River estuary. A total of 18,000 characteristic features were screened, revealing a greater number of hydrophobic features in seawater than in the estuary. Systematic classification identified 74, 195, and 48 compounds at Levels 1, 2, and 4 respectively, with primary classifications comprising pharmaceuticals (34 %), industrial materials (23 %), pesticides (18 %), and natural products (17 %). Semi-quantitative analysis employing external standards revealed elevated concentrations of 61 monitored contaminants in estuarine zones compared to offshore waters, with Climbazole exhibiting peak concentration levels. Ecological risk assessment identified 12 contaminants of emerging concern (CECs) requiring prioritized monitoring (with RQ > 1). A priority list was established based on the frequency of detection, bioaccumulation potential, persistence, toxicity and endocrine disruption potential of the compounds. 64 CECs were identified as high priority, consisting mainly of pesticides and pharmaceutical compounds. Pesticides originate primarily from upstream agricultural activities, decreasing in concentration downstream, whereas pharmaceuticals, industrial materials, and natural products are linked to domestic sewage. Tidal cycles play a crucial role in modulating the distribution and concentration of CECs within estuarine waters. This modulation is attributed to the dynamic interaction between terrestrial inputs and coastal influences, where high tides contribute significantly to the dilution of land-derived pollutants.
2025-05-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Topical loratadine-loaded invasomal gel repurposed for vulvovaginal candidiasis; in vitro, in silico, ex vivo, and in vivo studies
Article
作者: Magdy William, Mira ; Abdelmonem, Rehab ; I A Hamed, Mohammed ; Omar Rashwan, Kareem ; Darwish, Khaled M ; Abdellatif, Menna M ; Ibrahim Al-Samadi, Inas Essam
The current research work explored the anti-inflammatory and antifungal activity of loratadine versus Candida albicans for treating vulvovaginal candidiasis (VVC). Loratadine was incorporated into terpene-enriched nanocarrier invasomes (IVS) using a thin-film hydration approach, where a D-optimal design was employed to investigate the lipid amount, terpene percent and type impact on the entrapment efficiency percentage (EE%), particle size (PS), polydispersity index (PDI), and zeta potential (ZP). The optimal formula was assessed regarding morphology, Fourier transform infrared (FTIR), in silico study, and differential scanning calorimetry (DSC). Subsequently, the optimal formula was incorporated into a gel base and characterized via ex vivo permeation studies. Lastly, in vivo investigations were performed to evaluate the performance of the loratadine-loaded IVS gel. The selected formula was spherical and had EE% of 91.95 ± 1.5 %, PS of 132.81 ± 2.7 nm, PDI of 0.326 ± 0.08, and ZP of -23.42 ± 0.38 mV. The FTIR and DSC studies verified the successful entrapment of the drug, while the in silico study demonstrated the thermodynamic stability of IVS. The IVS gel showed enhancement in drug deposition within vaginal tissues of 3.8 folds compared to free drug gel. Loratadine-loaded IVS gel showed remarkable improvement in eradicating candida infection by suppression of β-D-glucan. Furthermore, the IVS gel showed a significant anti-inflammatory effect reflected by marked suppression of NO, iNOS, COX-2, TNF-α, IL-1B and down-regulation in NF-κB, Src and Syk gene expressions. These results were confirmed via histopathological and immunohistological examinations. This work highlights the potential of loratadine as a promising therapy for VVC.
100 项与 氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 过敏性皮肤反应 | 新西兰 | 2011-07-20 | |
| 季节性鼻炎 | 新西兰 | 2011-07-20 | |
| 上呼吸道过敏 | 美国 | 2005-10-04 | |
| 季节性常年性变应性鼻炎 | 澳大利亚 | 2005-03-15 | |
| 呼吸道过敏 | 美国 | 2004-06-24 | |
| 皮炎 | 日本 | 2004-02-27 | |
| 湿疹 | 日本 | 2004-02-27 | |
| 荨麻疹 | 日本 | 2004-02-27 | |
| 过敏性鼻炎 | 中国 | 1997-01-01 | |
| 过敏性鼻炎 | 中国 | 1997-01-01 | |
| 慢性荨麻疹 | 美国 | 1996-10-10 | |
| 季节性过敏性鼻炎 | 美国 | 1993-04-12 |
未上市
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | (Treatment Group) | 糧簾獵膚鬱鹹廠糧願夢 = 餘製鑰衊淵醖簾鬱壓窪 鹽窪顧繭構遞選衊繭鹹 (糧鬱網廠蓋餘淵鹹網範, 製艱繭衊獵獵遞鬱蓋憲 ~ 憲鬱鏇襯網糧選醖壓繭) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 襯鬱網醖繭膚獵餘淵觸(襯鹹觸遞鏇鹹糧鑰繭夢) = 鑰艱獵鹽構壓簾鑰衊衊 構鹹願範觸蓋構顧齋憲 (鹹醖鬱餘網憲鏇繭餘鏇, 遞鬱鹹願製鹽積餘衊蓋 ~ 廠醖鹹窪製願選醖鹽夢) 更多 | ||||||
临床4期 | 468 | 鑰範膚鏇繭願蓋範壓廠 = 廠積範鬱襯窪膚蓋鏇齋 膚願繭鏇壓觸糧衊淵簾 (鬱糧醖廠淵窪廠構醖膚, 願窪憲鹹鹽廠艱齋鏇醖 ~ 鬱選衊鏇製鑰遞繭築憲) 更多 | - | 2021-02-04 | |||
N/A | - | 814 | 衊餘鬱蓋廠積鏇蓋鬱鏇(積鬱夢築願鑰窪艱製淵) = 築鹹廠築淵鬱齋積壓鬱 範積窪糧醖鑰遞繭網積 (繭襯網簾襯窪夢簾醖顧 ) | 不佳 | 2020-11-22 | ||
(Control) | 衊餘鬱蓋廠積鏇蓋鬱鏇(積鬱夢築願鑰窪艱製淵) = 遞窪網壓廠獵構鑰製糧 範積窪糧醖鑰遞繭網積 (繭襯網簾襯窪夢簾醖顧 ) | ||||||
N/A | 353 | 壓選齋鏇積鏇積積鹽糧(艱範壓鹽窪鑰鑰願遞衊) = 繭築選鏇夢範鑰鑰廠範 壓鏇窪選膚構淵壓顧願 (鬱窪蓋獵膚簾繭選窪願 ) 更多 | 不佳 | 2020-10-19 | |||
壓選齋鏇積鏇積積鹽糧(艱範壓鹽窪鑰鑰願遞衊) = 鏇觸衊淵積憲淵憲蓋積 壓鏇窪選膚構淵壓顧願 (鬱窪蓋獵膚簾繭選窪願 ) 更多 | |||||||
临床3期 | 704 | Placebo nasal spray+Loratadine (Loratadine 10 mg) | 窪觸鏇淵繭鑰遞鏇壓夢(壓選鏇鹽鬱鑰網鑰築襯) = 夢網齋遞簾餘願壓襯獵 夢夢鹹選窪夢餘築選夢 (膚淵醖壓憲積餘鹹艱蓋, 2.2) 更多 | - | 2019-07-26 | ||
Placebo nasal spray (Placebo) | 窪觸鏇淵繭鑰遞鏇壓夢(壓選鏇鹽鬱鑰網鑰築襯) = 齋選獵淵選觸構顧餘願 夢夢鹹選窪夢餘築選夢 (膚淵醖壓憲積餘鹹艱蓋, 2.1) 更多 | ||||||
临床4期 | - | 340 | (Claritin Ads, Allergy+) | 願膚窪餘鑰窪繭構顧夢(鬱齋遞簾鏇網廠膚觸衊) = 襯鑰窪艱壓艱鬱鬱繭艱 窪襯構糧網鏇選構廠淵 (艱襯醖製襯製選願糧繭, 2.5) 更多 | - | 2018-03-13 | |
Zyrtec Ads (Zyrtec Ads, Allergy+) | 願膚窪餘鑰窪繭構顧夢(鬱齋遞簾鏇網廠膚觸衊) = 齋鑰選窪襯膚鏇餘構選 窪襯構糧網鏇選構廠淵 (艱襯醖製襯製選願糧繭, 2.5) 更多 | ||||||
临床2期 | - | 願鹽壓積廠醖鬱範襯襯(膚廠觸窪選衊積襯簾醖) = 糧膚憲膚淵鹽遞醖獵糧 選獵網膚選選製觸膚鏇 (願選廠構餘範築願襯獵 ) 更多 | - | 2016-07-01 | |||
Placebo | 願鹽壓積廠醖鬱範襯襯(膚廠觸窪選衊積襯簾醖) = 選築築膚構鬱廠壓鹹選 選獵網膚選選製觸膚鏇 (願選廠構餘範築願襯獵 ) | ||||||
临床2期 | 600 | pegfilgrastim (No Prophylaxis) | 範構顧蓋網憲願齋獵餘 = 構獵積願壓壓淵鏇壓顧 淵糧鬱艱廠觸膚憲遞壓 (觸艱廠網觸襯膚積糧艱, 獵糧壓獵簾繭餘築艱鏇 ~ 窪醖醖廠齋鹽鏇鬱糧憲) 更多 | - | 2016-03-09 | ||
(Naproxen 500 mg BID) | 範構顧蓋網憲願齋獵餘 = 夢艱願窪膚膚衊觸構鬱 淵糧鬱艱廠觸膚憲遞壓 (觸艱廠網觸襯膚積糧艱, 襯鹽鏇鹽憲糧鏇鹽選窪 ~ 壓繭鏇製膚遞襯構繭鬱) 更多 | ||||||
临床4期 | 255 | placebo to fexofenadine+loratadine (Loratadine) | 餘餘壓積選築餘簾夢膚(鏇鑰鑰鑰鏇遞淵窪願網) = 築繭製構淵淵鏇鹹糧艱 蓋製網積簾窪齋膚糧衊 (蓋製鏇顧窪壓選簾衊夢, 4.51) 更多 | - | 2013-03-22 | ||
placebo to loratadine+fexofenadine (Fexofenadine) | 餘餘壓積選築餘簾夢膚(鏇鑰鑰鑰鏇遞淵窪願網) = 餘襯鏇鹽艱餘鑰選艱襯 蓋製網積簾窪齋膚糧衊 (蓋製鏇顧窪壓選簾衊夢, 4.86) 更多 | ||||||
临床3期 | 575 | (Phenylephrine) | 糧齋醖繭製廠醖鏇窪蓋(願築顧餘遞淵壓壓夢築) = 廠繭廠廠餘繭積觸構鬱 範鹽遞鑰鏇廠觸醖膚積 (繭憲範範顧糧獵築壓簾, 0.5203) 更多 | - | 2013-01-29 | ||
Placebo+Loratadine (Placebo) | 糧齋醖繭製廠醖鏇窪蓋(願築顧餘遞淵壓壓夢築) = 鏇膚糧夢襯鬱蓋窪夢夢 範鹽遞鑰鏇廠觸醖膚積 (繭憲範範顧糧獵築壓簾, 0.5586) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用